Takeda and seagen to highlight adcetris® combination data showing statistically significant improvement in overall survival (os) for patients with advanced hodgkin lymphoma

Cambridge, mass. & osaka, japan & bothell, wash.--(business wire)--takeda pharmaceutical company limited (tse:4502) and seagen inc., (nasdaq:sgen) today announced that overall survival (os) data from the phase 3 echelon-1 clinical trial of an adcetris® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th american society of clinical oncology (asco) annual meeting on friday, june 3, 2022, 1:00-4:00 pm ct, and at the 27th european hematology associa
SGEN Ratings Summary
SGEN Quant Ranking